Gilead Sciences, Inc. (GILD) — closed signal from December 19, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 19, 2026 — +14% at the close.
Predicted vs. what happened
What happened
Reached its target in 39 days.
The thesis — published December 19, 2025
Gilead is a steady buy-for-holding over the next few months rather than a fast mover. Recent Phase 3 results for a new HIV drug matched a top competitor, and a new senior legal hire may help the company run smoother. Expect gains to come gradually as investors slowly revalue the stock; wider market shifts away from defensive healthcare could limit upside.
Primary drivers
- New Phase 3 HIV results increase confidence in future drug options
- Senior legal hire reduces uncertainty about company execution
- Steady earnings make the stock attractive in volatile markets
- Weaker buy signals mean gains may be slower and stay in a range
How it played out
GILD: target reached in 39 days
Lyra published GILD at $123.8 on 2025-12-19 with a short-term view and expected growth of 12%. The thesis pointed to new Phase 3 HIV results, a senior legal hire, steady earnings in volatile markets, and weaker buy signals that could make gains slower and range-bound.
Inside the window, the stock reached the $138.66 target in 39 days. It later peaked at $157.29 on 2026-02-11, with a peak gain of 27.1%. By 2026-03-19 it ended at $141.11, still above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.